Case Report: Pancreatic metastasis of renal cell carcinoma 16 years after nephrectomy
BackgroundRenal cell carcinoma (RCC) is the most common renal malignancy, and may metastasize to different sites in the body via hematogenous and lymphomatous routes. The pancreas is a rare metastatic site of metastatic RCC (mRCC) and isolated pancreatic metastasis of RCC (isPMRCC) is even rarer.Res...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-02-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1091635/full |
| _version_ | 1828038190063157248 |
|---|---|
| author | Yidan Lou Yidan Lou Kaibo Guo Kaibo Guo Song Zheng Song Zheng Song Zheng Song Zheng |
| author_facet | Yidan Lou Yidan Lou Kaibo Guo Kaibo Guo Song Zheng Song Zheng Song Zheng Song Zheng |
| author_sort | Yidan Lou |
| collection | DOAJ |
| description | BackgroundRenal cell carcinoma (RCC) is the most common renal malignancy, and may metastasize to different sites in the body via hematogenous and lymphomatous routes. The pancreas is a rare metastatic site of metastatic RCC (mRCC) and isolated pancreatic metastasis of RCC (isPMRCC) is even rarer.ResultsThe present report describes a case of isPMRCC that recurred 16 years after surgery. The patient responded well to the treatment with pancreaticoduodenectomy and systemic therapy, and no recurrence was recorded after 2 years.ConclusionsisPMRCC is a distinct subgroup of RCC with unique clinical characteristics that may be explained by its underlying molecular mechanisms. Surgery and systemic therapy confer survival benefits to patients with isPMRCCs, although the recurrence problem has to be paid attention to. |
| first_indexed | 2024-04-10T16:23:11Z |
| format | Article |
| id | doaj.art-1779c1bea78d4a63a614bb64276b665f |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-10T16:23:11Z |
| publishDate | 2023-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-1779c1bea78d4a63a614bb64276b665f2023-02-09T10:32:09ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-02-011310.3389/fonc.2023.10916351091635Case Report: Pancreatic metastasis of renal cell carcinoma 16 years after nephrectomyYidan Lou0Yidan Lou1Kaibo Guo2Kaibo Guo3Song Zheng4Song Zheng5Song Zheng6Song Zheng7Department of Oncology, Affilited Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaZhejiang University School of Medicine, Hangzhou, ChinaDepartment of Oncology, Affilited Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaDepartment of Oncology, The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, ChinaDepartment of Oncology, Affilited Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaDepartment of Oncology, The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, ChinaDepartment of Oncology, Affiliated Hangzhou Cancer Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaKey Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaBackgroundRenal cell carcinoma (RCC) is the most common renal malignancy, and may metastasize to different sites in the body via hematogenous and lymphomatous routes. The pancreas is a rare metastatic site of metastatic RCC (mRCC) and isolated pancreatic metastasis of RCC (isPMRCC) is even rarer.ResultsThe present report describes a case of isPMRCC that recurred 16 years after surgery. The patient responded well to the treatment with pancreaticoduodenectomy and systemic therapy, and no recurrence was recorded after 2 years.ConclusionsisPMRCC is a distinct subgroup of RCC with unique clinical characteristics that may be explained by its underlying molecular mechanisms. Surgery and systemic therapy confer survival benefits to patients with isPMRCCs, although the recurrence problem has to be paid attention to.https://www.frontiersin.org/articles/10.3389/fonc.2023.1091635/fullrenal cell carcinoma (RCC)late recurrencegeneticsVHLPtenKDM5C |
| spellingShingle | Yidan Lou Yidan Lou Kaibo Guo Kaibo Guo Song Zheng Song Zheng Song Zheng Song Zheng Case Report: Pancreatic metastasis of renal cell carcinoma 16 years after nephrectomy Frontiers in Oncology renal cell carcinoma (RCC) late recurrence genetics VHL Pten KDM5C |
| title | Case Report: Pancreatic metastasis of renal cell carcinoma 16 years after nephrectomy |
| title_full | Case Report: Pancreatic metastasis of renal cell carcinoma 16 years after nephrectomy |
| title_fullStr | Case Report: Pancreatic metastasis of renal cell carcinoma 16 years after nephrectomy |
| title_full_unstemmed | Case Report: Pancreatic metastasis of renal cell carcinoma 16 years after nephrectomy |
| title_short | Case Report: Pancreatic metastasis of renal cell carcinoma 16 years after nephrectomy |
| title_sort | case report pancreatic metastasis of renal cell carcinoma 16 years after nephrectomy |
| topic | renal cell carcinoma (RCC) late recurrence genetics VHL Pten KDM5C |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1091635/full |
| work_keys_str_mv | AT yidanlou casereportpancreaticmetastasisofrenalcellcarcinoma16yearsafternephrectomy AT yidanlou casereportpancreaticmetastasisofrenalcellcarcinoma16yearsafternephrectomy AT kaiboguo casereportpancreaticmetastasisofrenalcellcarcinoma16yearsafternephrectomy AT kaiboguo casereportpancreaticmetastasisofrenalcellcarcinoma16yearsafternephrectomy AT songzheng casereportpancreaticmetastasisofrenalcellcarcinoma16yearsafternephrectomy AT songzheng casereportpancreaticmetastasisofrenalcellcarcinoma16yearsafternephrectomy AT songzheng casereportpancreaticmetastasisofrenalcellcarcinoma16yearsafternephrectomy AT songzheng casereportpancreaticmetastasisofrenalcellcarcinoma16yearsafternephrectomy |